Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Triana Biomedicines Taps Dr. Mohan Bala as Chief Operating Officer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Triana Biomedicines Taps Dr. Mohan Bala as Chief Operating Officer

Bala offers 30+ years of industry experience in program leadership, program development, market access, product strategy, and business development.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Triana Biomedicines Inc., a biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, has appointed Dr. Mohan Bala as Chief Operating Officer (COO).

Bala brings more than 30 years of industry experience in program leadership, program development, market access, product strategy, and business development to Triana. His expertise spans the full development continuum, from early to late-stage programs, across both small biotech and large pharmaceutical organizations.

Prior to joining Triana, he served as Chief Development Officer at Mersana Therapeutics, where he played a key role in business development efforts that culminated in the company’s acquisition by Day One Biopharmaceuticals. Before that, he was Chief Operating Officer at Constellation Pharmaceuticals, where he led multiple development functions, while also contributing significantly to the business activities that led to the company’s acquisition by MorphoSys. Earlier in his career, Bala held roles of increasing responsibility at TESARO, Sanofi, GlaxoSmithKline, Centocor, and Research Triangle Institute. He holds a PhD in Management Science from the University of Chicago.

“I’m excited to join Triana at this stage of its development. I was attracted by the Company’s molecular glue technology, the experience and vision of the leadership team, and the opportunity to advance a pipeline focused on patients with significant unmet needs,” said Bala. “I am particularly encouraged by the potential of TRI-611 for ALK+ NSCLC and look forward to working with the team as Triana continues to advance more of its pipeline programs into the clinic.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics